Navigation Links
Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
Date:3/22/2011

PITTSBURGH, March 22, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S. distribution rights of Humeca products. Humeca, which is based in the Netherlands, has a portfolio that includes products used by burn, plastic and reconstructive surgeons to repair skin defects.

Mylan Institutional President Matt Erick commented: "Mylan Institutional is extremely pleased to have found a partner as strong as Humeca to accelerate our growth in the burn and wound care space. For the first time in the U.S., plastic and reconstructive surgeons will have access to Humeca's modified MEEK micrografting system, the method of choice for skin transplantation. The addition of Humeca's innovative products to UDL's established line of advanced wound and burn care products positions Mylan Institutional for growth in this sector."

Humeca's modified MEEK micrografting system greatly reduces the donor surface area required for skin transplantation when compared to the commonly-used mesh graft technique. This is especially useful for treating patients with large burns who have limited donor tissue availability.

UDL Laboratories is part of Mylan Institutional, a platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clini
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender ... (NASDAQ: VPHM).   As a result of the ... and Shire expects to complete the tender offer on January ... the satisfaction of all of the remaining conditions to the ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nasdaq: NVGN ), announced today that following ... held on 7 May, 2012, its Board of Directors ... Marshall Edwards, Inc. ("MEI") under the MEI rights offering ... rights that have not been otherwise exercised by MEI ...
... 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ), ... novel therapeutics targeting cancer metabolism, announced that its majority ... million of Units, subject to availability, in Marshall Edwards, ... Novogen stockholders in Sydney on Monday. Pursuant ...
Cached Medicine Technology:Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 30 (HealthDay News) -- Parents who smoke are more likely to ... but their chances of success aren,t any better than normal, a ... an important role in helping these parents quit smoking, said the ... included 1,112 children who lived with at least one person who ...
... health problems have higher mortality rates than patients without ... 30 in the Journal of the National Cancer ... heart attack and other heart-related problems, chronic obstructive pulmonary ... that comorbidities as a group are associated with poorer ...
... consider the impact of gender on patient outcomes in major ... found that women are more likely to survive after the ... comparing women before menopause with men of the same age. ... Surgical Research in a paper titled "The Battle of ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, June ... it is to remember things that never happened, especially if ... British and Israeli researchers used a novel false-memory test and ... About 70 percent of those who took part in the ...
... Johns Hopkins have provided more clues to one of the ... of cellular DNA, called telomeres, lengthen instead of shorten. ... Express, the Johns Hopkins researchers say they have identified ... Telomeres contain repeated sequences of DNA that, in normal ...
... new study published in the American Journal of Transplantation ... skin cancers, including cutaneous squamous cell carcinoma and melanoma, ... they need immune medications to keep their body from ... they experience as a result of the medications can ...
Cached Medicine News:Health News:A Child's Surgery May Prompt Parents to Try to Quit Smoking 2Health News:Worse outcomes for older breast cancer patients with other health problems 2Health News:Women win out in gastrointestinal surgery 2Health News:Group-Think Can Influence Your Memory, Research Shows 2Health News:Telomeres: 2 genes linked to why they stretch in cancer cells 2Health News:Telomeres: 2 genes linked to why they stretch in cancer cells 3
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: